Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Placebo-Controlled, Double-Blind, Phase 2 Study to Select the Optimal Dose(s) of Fezolinetant in Women Suffering From Vasomotor Symptoms (Hot Flashes) Associated With Menopause in Japan

NCT05034042 is registered in ClinicalTrials.gov with Astellas Pharma Inc as lead sponsor.

NCT NCT05034042
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05034042 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Placebo-Controlled, Double-Blind, Phase 2 Study to Select the Optimal Dose(s) of Fezolinetant in Women Suffering From Vasomotor Symptoms (Hot Flashes) Associated With Menopause in Japan
Lead sponsor
Astellas Pharma Inc
Phase
Phase 2
Overall status
Completed
Start date
November 17, 2021
Completion date
December 23, 2022
Enrollment
147 (actual)
Sites
40

Conditions

As the registry lists them; a condition with its own page is linked.

hot flashes